Abstract:Guided by molecular docking, a commonly used open-chain linker was cyclized into a five-membered pyrrolidine to lock the overall conformation of the propeller-shaped molecule. Different substituents were introduced into the pyrrolidine moiety to block oxidative metabolism. Surprisingly, it was found that a small methyl substituent could be used to alleviate the oxidative metabolism of pyrrolidine while maintaining or enhancing potency, which could be described as a "magic methyl". Further optimization around the "3rd blade" of the propeller led to identification of a series of potent and selective PI3Kδ inhibitors. Among them, compound 50 afforded an optimum balance of PK profiles and potency. Oral administration of 50 attenuated the arthritis severity in a dose-dependent manner in a collagen-induced arthritis model without obvious toxicity. Furthermore, 50 demonstrated excellent pharmacokinetic properties with high bioavailability, suggesting that 50 might be an acceptable candidate for treatment of inflammatory diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00004?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00004</a>.Binding affinities of 50 with 164 kinases (Table S1); predicted results of compound 43 from the CYP3A4, CYP2D6, and CYP2C9 models, respectively, in SMARTCyp (Tables S2–S4); effects of compound 50 and idelalisib on normal cell viability (Table S5); binding free energy (ΔGbindcal) for idelalisib/PI3Kδ complexes (Table S6); binding free energy (ΔGbindcal) for compound 50/PI3Kδ complexes (Table S7); cocrystal structure of 1 in PI3Kδ (Figure S1); docking model of compound 29 in PI3Kδ (Figure S2); pre-experiments of selected compounds and dexamethasone in collagen-induced arthritis models (Figure S3); snapshots of the idelalisib/PI3Kδ complex along the dynamic simulation time for 100th, 200th, 300th, 400th, and 500th ns (Figure S4); snapshots of the compound 50/PI3Kδ complex along the dynamic simulation time at 100th, 200th, 300th, 400th, and 500th ns (Figure S5); therapeutic efficacy of 50 in mice-established collagen-induced arthritis (Figure S6); HPLC spectra of compound 50 (Figure S6); 1H NMR spectra of compounds 26, 30, 45, 46, 47, 49, and 50 (Figures S8, S9, S10, S11, S12, S13, and S14, respectively); and biological assay methods: (1) kinase profile assay and IC50 test; (2) class I PI3K isoform-selective cellular assays (SKOV-3, 786-O, RAW 264.7, and RAJI cell lines); (3) basophil activation assay in HWB; (4) B cell activation assay in HWB; (5) primary human T-cell proliferation assays; (6) microsome stability assay; (7) pharmacokinetic study; (8) collagen-induced arthritis (CIA) model and treatment; and (9) histological examination (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_003.csv">CSV</a>)PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a> was used for docking in PI3Kδ of compounds 10, 29, 43, and 50 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_002.zip">ZIP</a>)This article has not yet been cited by other publications.

Structurally Novel PI3Kδ/γ Dual Inhibitors Characterized by a Seven-Membered Spirocyclic Spacer: the SARs Investigation and PK Evaluation.

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Discovery of Pyrazolo[1,5- a ]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Discovery of a Series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides As PI3K/mTOR Dual Inhibitors

Discovery of Pyrazolo[1,5- a ]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors

Identification, Structure–Activity Relationships of Marine-Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy

Conformationally Restricted Quinazolone Derivatives As PI3Kδ-selective Inhibitors: the Design, Synthesis and Biological Evaluation.

Discovery and Synthesis of a Novel Series of Potent, Selective Inhibitors of the PI3Kα: 2-Alkyl-chromeno[4,3-c]pyrazol-4(2h)-one Derivatives.

Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases

Exploration of (S)-3-aminopyrrolidine As a Potentially Interesting Scaffold for Discovery of Novel Abl and PI3K Dual Inhibitors.

Novel 4-Acrylamido-quinoline Derivatives As Potent PI3K/mTOR Dual Inhibitors: the Design, Synthesis, and in Vitro and in Vivo Biological Evaluation.

Design, synthesis, and biological evaluation of novel bivalent PI3K inhibitors for the potential treatment of cancer

Design And Synthesis Of A Novel Series Of N,4-Diphenylpyrimidin-2-Amine Derivatives As Potent And Selective Pi3k Gamma Inhibitors

Bis(Morpholino-1,3,5-Triazine) Derivatives: Potent Adenosine 5 '-Triphosphate Competitive Phosphatidylinositol-3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (Pki-587), A Highly Efficacious Dual Inhibitor

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.

Design, Synthesis and Biological Evaluation of Novel 4-Alkynyl-quinoline Derivatives As PI3K/mTOR Dual Inhibitors.

Design, Synthesis and in Vitro Biological Evaluation of 2-Aminopyridine Derivatives As Novel PI3Kδ Inhibitors for Hematological Cancer.